Tango Therapeutics (NASDAQ:TNGX) Stock Price Expected to Rise, HC Wainwright Analyst Says

Tango Therapeutics (NASDAQ:TNGX) had its price objective upped by equities research analysts at HC Wainwright from $13.00 to $27.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 59.29% from the company’s current price.

TNGX has been the subject of a number of other research reports. Stifel Nicolaus initiated coverage on shares of Tango Therapeutics in a research report on Wednesday, December 3rd. They issued a “buy” rating and a $15.00 price objective for the company. Wolfe Research began coverage on Tango Therapeutics in a research note on Tuesday, November 18th. They set a “peer perform” rating for the company. B. Riley Financial lifted their price target on Tango Therapeutics from $8.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. Guggenheim upped their price objective on Tango Therapeutics from $12.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Finally, Wall Street Zen upgraded Tango Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $18.25.

Tango Therapeutics Stock Up 0.7%

Shares of TNGX stock opened at $16.95 on Friday. The stock has a market capitalization of $2.28 billion, a PE ratio of -19.48 and a beta of 1.76. Tango Therapeutics has a 52-week low of $1.03 and a 52-week high of $17.63. The stock’s 50-day moving average price is $11.86 and its 200 day moving average price is $9.46.

Tango Therapeutics (NASDAQ:TNGX) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.02. Tango Therapeutics had a negative return on equity of 66.01% and a negative net margin of 151.15%. Analysts expect that Tango Therapeutics will post -1.19 earnings per share for the current fiscal year.

Insider Buying and Selling at Tango Therapeutics

In related news, Director Barbara Weber sold 30,519 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total value of $374,162.94. Following the transaction, the director directly owned 1,629,254 shares of the company’s stock, valued at approximately $19,974,654.04. This trade represents a 1.84% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Daniella Beckman sold 10,317 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total value of $126,486.42. Following the transaction, the chief financial officer owned 184,297 shares in the company, valued at approximately $2,259,481.22. This represents a 5.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 113,633 shares of company stock worth $1,420,857 in the last 90 days. 7.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Tango Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of TNGX. Seven Fleet Capital Management LP acquired a new position in shares of Tango Therapeutics in the 4th quarter valued at approximately $1,906,000. XTX Topco Ltd acquired a new position in Tango Therapeutics during the 4th quarter worth $335,000. VARCOV Co. bought a new stake in shares of Tango Therapeutics in the 4th quarter worth about $261,000. Virtus Investment Advisers LLC raised its stake in shares of Tango Therapeutics by 26.3% in the 4th quarter. Virtus Investment Advisers LLC now owns 28,452 shares of the company’s stock valued at $252,000 after purchasing an additional 5,920 shares in the last quarter. Finally, Tudor Investment Corp ET AL raised its stake in shares of Tango Therapeutics by 27.4% in the 4th quarter. Tudor Investment Corp ET AL now owns 68,251 shares of the company’s stock valued at $605,000 after purchasing an additional 14,679 shares in the last quarter. Hedge funds and other institutional investors own 78.99% of the company’s stock.

Tango Therapeutics News Roundup

Here are the key news stories impacting Tango Therapeutics this week:

• Positive Sentiment: Clinical collaboration with Erasca to test ERAS‑0015/vopimetostat in MTAP‑deleted, RAS‑mutant cancers expands Tango’s clinical footprint and creates near‑term partnership newsflow that likely drove buying interest and record highs. TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS
• Positive Sentiment: HC Wainwright sharply raised its price target to $27 (buy), a large explicit upside that can boost sentiment and buy‑side conviction. HC Wainwright price target raise
• Positive Sentiment: Guggenheim raised its target to $20 and reiterated a buy rating, adding to analyst momentum and supporting the share‑price lift. Guggenheim price target raise
• Positive Sentiment: Wedbush raised its target to $19 with an “outperform” rating, another vote of confidence from sell‑side analysts that can attract new buyers. Wedbush price target raise
• Positive Sentiment: An investment firm added ~1.1M shares (~$9.5M), increasing its reported position materially — institutional buying that signals conviction and can underpin the rally. Investment Firm Bets Big on TNGX Stock
• Neutral Sentiment: Quarterly results beat EPS estimates by $0.02 (reported -$0.29 vs. -$0.31) — a modest positive but company remains unprofitable with negative margins and ROE, so financials are unlikely to change valuation narrative immediately. Tango Therapeutics press release
• Negative Sentiment: A Seeking Alpha piece warns against buying into the rally despite PRMT5 promise, highlighting clinical, competitive and valuation risks that could limit upside or prompt pullbacks if trial data or execution falter. Tango Therapeutics: I’m Not Buying Into Latest Rally

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.